OPKO Health saw the highest growth of 1.32% in patent filings in April and 2.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.32% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of OPKO Health‘s patent filings and grants. Buy the databook here.
OPKO Health has been focused on protecting inventions in Australia(AU) with five publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings with nearly 28% of filings. The Australia(AU), Israel(IL), United States(US), and China(CN) patent Office are among the top ten patent offices where OPKO Health is filings its patents. Among the top granted patent authorities, OPKO Health has 25% of its grants in European Patent Office(EPO), 8% in Israel(IL) and 8% in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for OPKO Health
Patents related to rare diseases and Covid-19 lead OPKO Health's portfolio
OPKO Health has the highest number of patents in rare diseases followed by, Covid-19 and healthtech. For rare diseases, nearly 27% of patents were filed and 6% of patents were granted in Q2 2024.
Healthcare it related patents lead OPKO Health portfolio followed by growth hormone deficiency, and severe acute respiratory syndrome (sars)
OPKO Health has highest number of patents in healthcare it followed by growth hormone deficiency, severe acute respiratory syndrome (sars), laboratory equipment, and chronic kidney disease (chronic renal failure). For healthcare it, nearly 11% of patents were filed and 30% of patents were granted in Q2 2024.
For comprehensive analysis of OPKO Health's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.